Description du projet
Surveillance en temps réel de la fonction cardiaque après une opération à cœur ouvert
La chirurgie à cœur ouvert est une opération à haut risque au cours de laquelle la poitrine est ouverte pour exposer le cœur. Elle requiert une surveillance continue de la fonction cardiaque pour déceler les complications potentielles, mais les technologies actuelles ne parviennent pas à fournir des données en temps réel et précises pendant et après l’opération. Le projet SAMBAfun, financé par l’UE, répond à ce besoin médical non comblé grâce à un nouveau capteur qui peut être incorporé dans les sondes épicardiques temporaires existantes des stimulateurs cardiaques. En un mot, l’innovation permet de mesurer la vitesse de chaque contraction cardiaque, ce qui est vital pour surveiller la fonction cardiaque. Les données s’affichent sur un moniteur et peuvent alerter le personnel médical de toute complication consécutive à une chirurgie cardiaque.
Objectif
In patients undergoing open-heart surgeries, perioperative cardiac monitoring is used to track the functioning of the heart and identify complications. However, myocardial failure and other severe complications can escape detection using current monitoring technologies, given the trade-offs between invasiveness, real time measurements, accessibility and accuracy of data. Given the high-risk profile of these surgeries, failure to timely detect complications leads to increased mortality and morbidity, which in turn results in increased hospitalization costs and lower quality of life for the affected patients.
For effective cardiac monitoring, surgeons need real time data, 24h continuous monitoring during and post-surgery, and an accurate biosignal marker that can be trusted for immediate detection and assessment of cardiac events. No current technology enables this with low invasiveness and risk.
Cardiaccs (SME) and Osypka (SME) will bring to market a patented solution that involves adding a 3-axis accelerometer to a standard epicardial pace lead, which is routinely used for most cardiac surgical patients, to assess cardiac motion and contractility in real time, both during and after surgery – and up to 7 days. Data from CardiSense will appear on a monitor and an alert function will let surgeons and nurses know as soon as a complication is picked-up on the continuously analysed data.
SAMBAfun brings together 2 SMEs with complementary know-how, IPR and value chain positions. Cardiaccs patented the concept, whereas Osypka has 40 years of experience in developing cardiac pace leads. Osypka dominates the German market and has extensive ties to global distributors. Three leading research hospitals (Oslo, Aarhus and Berlin) will demonstrate the latest advances in this device, provide Key Opinion Leader input and contribute with multi-market, highly credible data for regulatory certification and health economic models to support reimbursement applications in all markets.
Champ scientifique
- social sciencessociologydemographymortality
- medical and health sciencesclinical medicinesurgery
- natural scienceschemical sciencesinorganic chemistrypost-transition metals
- medical and health sciencesclinical medicinecardiology
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
Mots‑clés
Programme(s)
Régime de financement
IA - Innovation actionCoordinateur
0458 Oslo
Norvège
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.